U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula As
Molecular Weight 74.9216
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 3

SHOW SMILES / InChI
Structure of ARSENIC CATION (3+)

SMILES

[As+3]

InChI

InChIKey=LULLIKNODDLMDQ-UHFFFAOYSA-N
InChI=1S/As/q+3

HIDE SMILES / InChI
Arsenic trioxide (ATO) is used to treat acute promyelocytic leukemia in people who have not been helped by other types of chemotherapy or whose condition has improved but then worsened following treatment with other types of chemotherapy. Arsenic trioxide acts through activation of Jun N-terminal kinase (JNK), activator protein-1, and inhibition of dual-specificity phosphatases. Although the exact mechanisms under which ATO exerts its therapeutic effect in acute promyelocytic leukemia cancer cells are not well elucidated. It was shown that apoptotic mechanisms involved the induction of phosphatidylserine externalization, caspase-3 activation, and nucleosomal DNA fragmentation. Adverse reactions described are leukocytosis, nausea, vomiting, diarrhea, and abdominal pain, fatigue, edema, hyperglycemia, dyspnea, cough, rash or itching, headaches, and dizziness.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: activator protein-1
Target ID: dual-specificity phosphatases
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TRISENOX

Approved Use

Acute promyelocytic leukemia (newly diagnosed) (low-risk disease): Treatment of newly diagnosed low-risk acute promyelocytic leukemia (APL), in combination with tretinoin, in adults whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression Acute promyelocytic leukemia (relapsed or refractory): Remission induction and consolidation treatment of APL in patients who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression

Launch Date

9.6984E11

Sample Use Guides

Induction Treatment Schedule: TRISENOX™ should be administered intravenously at a dose of 0.15 mg/kg daily until bone marrow remission. Total induction dose should not exceed 60 doses. Consolidation Treatment Schedule: Consolidation treatment should begin 3 to 6 weeks after completion of induction therapy. TRISENOX™ should be administered intravenously at a dose of 0.15 mg/kg daily for 25 doses over a period up to 5 weeks.
Route of Administration: Intravenous
Name Type Language
ARSENIC CATION (3+)
Common Name English
ARSENIC (III)
Systematic Name English
ARSENIC ION(3+)
Common Name English
ARSENIC(3+) ION
Common Name English
ARSENIC CATION (AS3+)
Common Name English
ARSENIC(+3)
Systematic Name English
ARSENIC, ION (AS3+)
Common Name English
ARSENIC CATION (3)
Common Name English
AS3+
Common Name English
ARSENIC III
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C68234
Created by admin on Sat Jun 26 08:37:08 UTC 2021 , Edited by admin on Sat Jun 26 08:37:08 UTC 2021
Code System Code Type Description
FDA UNII
C96613F5AV
Created by admin on Sat Jun 26 08:37:08 UTC 2021 , Edited by admin on Sat Jun 26 08:37:08 UTC 2021
PRIMARY
NCI_THESAURUS
C68235
Created by admin on Sat Jun 26 08:37:08 UTC 2021 , Edited by admin on Sat Jun 26 08:37:08 UTC 2021
PRIMARY
PUBCHEM
104734
Created by admin on Sat Jun 26 08:37:08 UTC 2021 , Edited by admin on Sat Jun 26 08:37:08 UTC 2021
PRIMARY
EPA CompTox
22541-54-4
Created by admin on Sat Jun 26 08:37:08 UTC 2021 , Edited by admin on Sat Jun 26 08:37:08 UTC 2021
PRIMARY
CAS
22541-54-4
Created by admin on Sat Jun 26 08:37:08 UTC 2021 , Edited by admin on Sat Jun 26 08:37:08 UTC 2021
PRIMARY